Treatment of human immunodeficiency virus and hepatitis B virus infections.
Whilst virally attenuated clotting factor concentrates are now safe with respect to transmission of HBV and HIV there are many individuals with haemophilia who were infected many years ago by these viruses. New combination therapies are available for treating both these virus infections and efficacy rates are increasing. Although many of the clinical studies are initially undertaken in non-haemophilia individuals, consideration needs to be given as to the possible benefits of including those with haemophilia in the clinical assessment.